Bio-Rad Laboratories has introduced three StarBright dyes designed for flow cytometry applications.
StarBright Violet 570, 670, and 710 dyes offer improved brightness and precise excitation and emission spectra, making them suitable for use in multicolour flow cytometry panels. Bio-Rad’s line of StarBright dyes offers researchers a range of fluorescent nanoparticles conjugated to highly validated flow antibodies.
“The new StarBright dyes offer improved brightness when compared to other available dyes at similar wavelengths, and they may be used with a wide range of flow cytometers,” said Mike Blundell, PhD, Bio-Rad Product Manager, Flow Cytometry, Life Science Group. “The unique profile of the dyes offers enhanced resolution of rare populations and low-density antigens as well as consistent and reproducible staining.”
Key benefits of StarBright dyes
Compatible with new and existing protocols and suitable for use in multiplex panels
Resistant to photobleaching and highly stable with minimal lot-to-lot variation
Offer reliable Förster resonance energy transfer (FRET) for reproducible data
Work with common staining buffers, including special polymer dye staining buffers, for easy integration into multicolour panels
Ensure no loss of signal in fixation
Offer narrow excitation and emission profiles for improved resolution in new and existing multicolour flow cytometry experiments
The StarBright Dyes are compatible with Bio-Rad’s ZE5 Cell Analyzer, S3e Cell Sorter, and other conventional and spectral flow cytometers.
Avacta Group, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU allowing the company to market the product in the EU for professional use.
Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others. The clinical data for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test reported 20 April 2021, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct<27.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “The EU is an important market for us, and the product registration is a key commercialisation milestone.
“The results of the recent clinical evaluation of the test at a clinical site in Europe demonstrate the test has excellent sensitivity across a range of viral loads, which would be considered infectious. This excellent performance and ease of nasal sampling, coupled with the fact that the AffiDX test is has been developed in the UK, is based on UK technology and is manufactured in the UK, are huge selling points for customers in Europe.”
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/avacta.jpg8041222panglobalhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngpanglobal2021-06-14 10:31:242021-06-14 10:31:24Avacta announces EU registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test
3Brain AG has introduced a new technology based on a unique combination of microchips and AI that promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials – and to maximize their chances of success.
Using CorePlate™ technology, preclinical cell assays are performed in multiwell plates that integrate a microchip in each well to collect rich information from cells, pre-process cell data and streamline it to the paired software. As a result, much more and better data can be extracted, which can be referred to as cell big data. This is fed to an AI with the aim of simplifying interpretation and enabling researchers to discover more information about drugs being tested.
Preclinical studies are vital for early identification of any safety and efficacy issues, and for increasing the chance of success of those drugs entering clinical trials. However, common estimates show that there is still a lot to improve in this area as 90% of the drugs that enter into human trials fail. Among the factors responsible for this high failure rate are the limitations of conducting preclinical tests on animal models. The vast majority of drugs that pass tests on animals do not later work on humans because disease mechanisms vary significantly between species.
New biotechnologies like human stem cells offer more successful alternatives to animal models. These may be in the form of cell culture assays or more sophisticated spheroid and organoid assays that can be used as testbeds for drugs. Human cell-based assays hold the promise to revolutionize drug development, improving the success rate and pushing animal tests towards extinction.
Whatever cell-based assay one wants to investigate, traditional approaches extract cell information via optical systems or a few sensors embedded in plastic substrates. Typically, these substrates are multiwell plates with 24, 96 or even more wells, where each well houses the cell samples to be measured. From these wells, the acquired information travels on limited bandwidth across long distances (compared to the cell size) before reaching a CPU where it gets processed. Long distances and bandwidth issues affect the quality and quantity of information and, consequently, prevent an accurate inspection of cell networks. The CorePlate technology devised by 3Brain disrupts this paradigm by bringing the processing unit in contact with the cells.
“We want to radically change the way preclinical drug screening is performed, offering pharmaceutical companies the opportunity to manage their pipelines more efficiently,” says Mauro Gandolfo, CEO and co-founder of 3Brain AG. “Basically, we take traditional plastic multiwell plates and we turn them into intelligent devices with multi-core processing power, which can be programmed according to research needs. Integrated intelligence is a remarkable distinction from other instruments in the preclinical space. Importantly, despite the large amounts of data CorePlate devices can process, the user can still easily generate results thanks to the AI-driven interpretation of data. With the CorePlate technology, pharmaceutical companies can save time and money by better filtering and prioritizing drug candidates. Our ultimate goal is to provide our users with tools that help them more readily identify new cures for diseases.”
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/3brain.jpg696926panglobalhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngpanglobal2021-06-14 10:20:042021-06-14 10:20:043Brain’s CorePlate technology combines microchips and AI in a revolutionary new approach to drug discovery
The new CE-marked SARS-CoV-2 NeutraLISA from EUROIMMUN provides fast and economical determination of the inhibiting effect of anti- SARS-CoV-2 antibodies in patient samples, serving as a surrogate virus neutralisation test.
Shimadzu, one of the world leaders in analytical instrumentation, has announced the release of the AOC-30 series of automatic sample injection systems for gas chromatographs.
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/Shimadzu_AOC-30-scaled.jpg25601969Shimadzu Europa GmbHhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngShimadzu Europa GmbH2021-06-07 14:56:192021-06-15 08:46:39Shimadzu introduces new AOC-30 Series automatic PRODUCT sample injection system
Quantitative assessment of antibodies in Covid-19 is becoming increasingly important. It provides information on the actual spread of infection in the population and enables characterization of a vaccine-induced immune response.
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/DiaSys.jpeg5961060DiaSys Diagnostic Systems GmbHhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngDiaSys Diagnostic Systems GmbH2021-06-07 12:35:342021-09-03 15:03:48DiaSys launches SARS-CoV-2 UTAB FS for reliable monitoring of total antibodies for SARS-CoV-2
Bio-Rad Laboratories has launched its Reliance SARS-CoV-2 RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements. The Reliance SARS-CoV-2 RT-PCR Kit is a real-time reverse-transcription PCR (RT-PCR) test that can detect nucleic acid in SARS-CoV-2, the virus associated with COVID-19 disease. A version of the assay kit is also available in the United States under an U.S. FDA emergency use authorization (EUA).
The Reliance SARS-CoV-2 RT-PCR Kit (IVD) is designed for clinical diagnostic labs that conduct COVID-19 testing. The assay kit offers the qualitative detection of two separate target regions in the nucleocapsid gene (N1 and N2 regions) of SARS-CoV-2 in nasopharyngeal swab specimens from individuals suspected of being infected by COVID-19.
Because the test are designed to target the nucleocapsid gene, the assay’s performance is not affected by known coronavirus variants as determined by in-silico analysis. The assay kit contains Bio-Rad’s standard and negative molecular controls as well as assay reagents. It is validated to run on Bio-Rad’s CFX96 Dx RT-PCR system, as well as RT-PCR systems from other manufacturers.
“We are excited about the European launch of our SARS-CoV-2 RT-PCR Kit (IVD), a reliable, sensitive, and accurate solution for COVID-19 testing,” said Steven Blakely, Bio-Rad Global Director of Marketing, Life Science Group, Gene Expression. “Testing laboratories worldwide use Bio-Rad’s RT-PCR systems for the detection of SARS-CoV-2. The assay kit is the latest addition to our COVID-19 offering of research and testing products, reflecting our ongoing commitment to helping in the fight against COVID-19,” he said.
https://clinlabint.com/wp-content/uploads/sites/2/2021/05/bio-rad_reliance.jpg594936panglobalhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngpanglobal2021-05-19 08:48:032021-05-19 08:48:03Bio-Rad launches its Reliance SARS-CoV-2 RT-PCR assay kit in Europe
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyse the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell culture workflows.
Whitney Ong, a joint chemistry graduate student in the Dodani and Smaldone labs at the university, explained: “My research focuses on the development of supramolecular-based sensors for anions, particularly for chloride. The reason we are especially interested in chloride is that it is the most abundant anion in the human body – serving all sorts of functions – and its dysregulation is implicated in diseases such as cystic fibrosis. We’re hoping that our chloride sensing platform could help in its detection, as well as in the diagnosis of a number of other diseases.”
Ong added: “We have three PIPETBOY pipette controllers and use them regularly for a variety of tasks during our cell culture set-up, for instance to make up large volumes of cell culture media, aliquoting and dispensing reagents such as media or antibiotics, resuspensions, as well as to mix different solutions. If we are working with volumes of liquids above 2 ml, we will always use the PIPETBOY; it’s much easier, safer and more efficient that pouring liquids between glass measuring cylinders, where there is a higher risk of spillages or not pouring out the desired volume. They fit into our workflows perfectly – everyone in the lab loves them.”
Shimadzu, one of the world leaders in analytical instrumentation, has released the TOC-1000e, the first analyzer in the eTOC series of on-line TOC analyzers designed for pure water applications. The eTOC series’ main focus is on miniaturization, high sensitivity and a mercury-free oxidation technique. The pioneering TOC-1000e system has the world’s smallest and lightest cabinet and provides high-sensitivity detection, making it ideal for fields requiring high-purity water applications. This covers manufacturing, including pharmaceuticals, semiconductors, food & beverages, chemistry and precision equipment.
Total organic carbon (TOC) analyzers are used to rapidly quantify organic substances in water, allowing decisive process intervention. Among many fields of application, they are used mainly for water quality control and environmental investigations. Shimadzu’s world-leading TOC analyzers are well-suited to laboratory and on-line analysis of environmental and waste water. The eTOC series will be Shimadzu’s first on-line TOC analyzer designed especially for pure water measurements.
The TOC-1000e provides enhanced robustness in the ultra-low measurement range. With its small footprint of less than A4 size, it can be installed flexibly – either as table-top, wall-mounted or pole-mounted.
Conventional TOC analyzers for pure water utilize mercury UV lamps as the light source within the instrument. To provide a more environmental-friendly alternative, the eTOC series is the first analyzer in the world to use an excimer (short for ‘excited dimer’) lamp rather than a mercury lamp.
The “Active-Path” flow line design maximizes lamp power by integrating the sample flow channel and the light source. This minimizes sample residue in the flow channel and eliminates interfering air layers, so high sensitivity is maintained over long-term use. This new design also contributes to making the eTOC series instruments small and light.
Features
The TOC-1000e combines high-sensitivity and easy-to-use features benefiting effortless data management, efficiency and handling.
Some of the features include:
State-of-the-art oxidation technology in the smallest casing The TOC-1000e provides high sensitivity with a detection limit of 0.1 μg/L. It is housed in the world’s smallest and lightest cabinet and equipped with the industry’s largest color touch panel, providing exceptional visibility, simplifying operation and allowing effortless management of compliance relevant data. In addition, the novel fluid system minimizes sample residue in the flow channel, ensuring that high sensitivity is maintained.
Easy-to-use and to maintain design improves efficiency The eTOC series has a simple design, and parts typically do not need to be replaced for one year; this increases efficiency by reducing maintenance and re-validation effort. Consumable parts (excimer lamp and pump head) can be removed and installed without tools. Using an optional sampler, the analyzer can be calibrated or validated (confirmation of manufacturing process validity) at the operating site. Certified standard solutions particularly for this series are available; they save customers the time and expense of purchasing and preparing items from a reagent manufacturer, and reduce mistakes caused by human error. In addition to analog interface and digital I/O, measurement data can be output to a printer or USB flash drive, or browsed and acquired via a built-in web server.
Support for Regulatory Compliance eTOC’s highly sensitive UV oxidation-conductivity method for ultra-pure water monitoring is compliant with regulatory requirements such as the United States (USP) and the European Pharmacopeia (EP). Inbuilt security functions including user authentication and audit trail, support compliance with regulations such as FDA 21 CFR Part 11. The LabSolutions software platform provides integrated management of the measurement data together with data and electronic signature functions (ER/ES) from laboratory TOC analyzers and other analytical instruments.
https://clinlabint.com/wp-content/uploads/sites/2/2021/05/Shimadzu_TOC_web.jpg11341701panglobalhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngpanglobal2021-05-11 12:44:292021-05-11 12:49:48Shimadzu releases online TOC analyzer designed for pure water applications
Vyon porous plastic discs and annular absorbers manufactured to extremely tight tolerances by Porvair Sciences offer cutting-edge filtration and separation of materials for healthcare, pharmaceutical and life science applications.
Drawing upon a wealth of knowledge in the manufacture of industry-leading porous plastics, combined with advanced materials expertise, Porvair Sciences has established a reputation for delivering outstanding hydrophilic components to OEM customers worldwide.
Employing precision moulding and die cutting processes, Porvair Sciences can efficiently convert hydrophilic Vyon® porous plastic into discs and annular shaped parts to tightly toleranced specifications. These versatile approaches enable Porvair to offer high performing, precisely manufactured products in diameters ranging from 3 mm to 1 metre using any of its hydrophilic Vyon materials options up to 4.75 mm thick.
Hydrophilically-treated Vyon materials have exceptional absorption and fluid transfer properties and therefore, can be implemented as an efficient absorber with its instantaneous wetting properties.
Due to the tortuous path of its porous structure, hydrophilic Vyon can efficiently filter and trap contaminants while allowing for effective delivery of drugs in various forms like solutions, suspensions and emulsions.
Hydrophilic Vyon has been tested to the most rigorous of USP classes and certified with a Class VI approval. Widely used in drug delivery and rapid diagnostic testing applications, its biocompatibility makes Vyon the ideal porous plastic material for healthcare, life science and pharmaceutical applications.
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.